KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 123 filers reported holding KEROS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $967,454 | -10.9% | 22,657 | +0.2% | 0.13% | -25.6% |
| Q4 2022 | $1,085,300 | +27.2% | 22,601 | -0.3% | 0.18% | +36.4% |
| Q3 2022 | $853,000 | -35.1% | 22,663 | -52.3% | 0.13% | +11.2% |
| Q2 2022 | $1,314,000 | +40.8% | 47,546 | +177.2% | 0.12% | +45.0% |
| Q1 2022 | $933,000 | +290.4% | 17,155 | +342.6% | 0.08% | +370.6% |
| Q1 2021 | $239,000 | – | 3,876 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |